Next, to further explore the potential for targeting DLK1 in ACC, we evaluated responses to ADCT-701 (1 mg/kg as a single dose18) among DLK1+ human ACC cell line-derived xenograft and ACC patient-derived xenograft (PDX) models (Fig. 3A, B). This evidence concerns the gene DLK1 and adrenal cortex carcinoma.